Hyperion To Pay Up To $600M For Israeli Diabetes Drug Co.
San Francisco biopharmaceutical company Hyperion Therapeutics is set to buy Israel-based Andromeda Biotech, a drug developer working on a new diabetes treatment, in a deal that could end up being worth...To view the full article, register now.
Already a subscriber? Click here to view full article